Advancing Our Pipeline
Our strategy of prioritization and sharper scientific inquiry has yielded a focused portfolio of promising drug candidates. As of year-end 2011, the Pfizer pipeline had 90 programs in process, from Phase I through registration. These included 70 new chemical entities, 23 additional indications, 49 small molecules, 24 biologics and three vaccines in development.
View the latest pipeline on Pfizer.com.